A few days after European Medicines Agency (EMA), o The US Food and Drug Administration (FDA) has approved it. vaccine respiratory syncytial virus (RSV) in the elderly.
The formulation was evaluated under the FDA’s accelerated review mechanism, as prevention of RSV infection in the elderly is considered an important public health goal, the scientists said.
The results showed that the vaccine protected 83% of older people from a lower respiratory tract infection (pneumonia), which is the main threat when they become infected with RSV. His defense lasts at least 6 months.
The vaccine contains a modified version of the fused RSV surface glycoprotein. This protein is the main target of antibodies produced to fight infection. When a person receives a vaccine, their immune system produces specific antibodies and T cells that help prevent RSV infection.
Adults infected with the virus usually have mild cold symptoms. Symptoms resemble an upper respiratory tract infection, which may include a runny nose, sore throat, cough, headache, fatigue, and fever.
The disease can be severe in vulnerable people, including the elderly, and people with lung or heart disease and diabetes. In Europe, RSV causes about 250,000 hospital admissions and 17,000 hospital deaths each year in people aged 65 and over.
According to CNBC
Source: Kathimerini
Ashley Bailey is a talented author and journalist known for her writing on trending topics. Currently working at 247 news reel, she brings readers fresh perspectives on current issues. With her well-researched and thought-provoking articles, she captures the zeitgeist and stays ahead of the latest trends. Ashley’s writing is a must-read for anyone interested in staying up-to-date with the latest developments.